🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced Head and Neck Squamous Cell Carcinoma

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites📍 Santa Rosa📍 Hartford📍 Washington D.C. VM Oncology, LLC · Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111Phase 1, Phase 252 sites📍 Pittsburgh📍 Natal📍 Porto Alegre Merck Sharp & Dohme LLC · Tests: Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU) Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma NCT05937438Phase 1, Phase 21 site📍 Hefei Anhui Provincial Hospital · Tests: Immune Checkpoint Inhibitors A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma NCT06843889Phase 21 site📍 Guangzhou Nanfang Hospital, Southern Medical University · Tests: Toripalimab (240mg day1, Q3W*3cycle) Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma NCT06988956Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Nimotuzumab, Tegafur, radiotherapy A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma) NCT07863141Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: anlotinib + PD-1 inhibitor, PD-1 inhibitor A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors NCT07814248Phase 13 sites📍 Maumee📍 Portland📍 Fairfax TwoStep Therapeutics, Inc. · Tests: TS-104 Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC NCT06100497Phase 21 site📍 Beijing Beijing Tongren Hospital · Tests: Pembrolizumab, Cisplatin, Paclitaxel-albumin Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer NCT07016724Phase 21 site📍 Zhengzhou The First Affiliated Hospital of Zhengzhou University · Tests: cadonilizumab combined with neoadjuvant radiochemotherapy, neoadjuvant radiochemotherapy Study of GV20-0251 in Participants With Solid Tumor Malignancies NCT07070518Phase 1, Phase 23 sites📍 Beijing📍 Beijing📍 Shanghai GV20 Therapeutics · Tests: GV20-0251 Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer NCT07667400Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: SX-682, DTX De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCC NCT06572514Phase 1, Phase 21 site📍 Shanghai Ruijin Hospital · Tests: immunotherapy：pembrolizumab；chemo：albumin-bound paclitaxel and cisplatin Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC NCT07403136Phase 21 site📍 Shanghai Fudan University · Tests: Vebrekotuzumab, PD-1 antibody A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709Phase 1, Phase 247 sites📍 Clovis📍 Los Angeles📍 Newport Beach Bristol-Myers Squibb · Tests: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma NCT07559045Phase 21 site📍 Zunyi Second Affiliated Hospital of Zunyi Medical University · Tests: Paclitaxel plus Cisplatin or Carboplatin (Induction Chemotherapy), Weekly Paclitaxel plus Cisplatin or Carboplatin (Con… Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma NCT06446726Phase 21 site📍 Chengdu Sichuan University · Tests: Tislelizumab, Low-dose radiotherapy, Nab-paclitaxel, Cisplatin Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma NCT06912074Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Induction chemoimmunotherapy, Hypofractionated Radiation Therapy, Conventional Fractionated Radiation Therapy, Concurre… Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors NCT05784688Phase 1, Phase 211 sites📍 San Antonio📍 Tyler📍 Spokane TiumBio Co., Ltd. · Tests: TU2218 + KEYTRUDA® (Pembrolizumab) Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC NCT07038629Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: S1, Iparomlimab, Radiation Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors NCT06535607Phase 298 sites📍 Los Angeles📍 Baltimore📍 New York AstraZeneca · Tests: Volrustomig, Cisplatin, Carboplatin, Paclitaxel, 5-FU A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043Phase 1, Phase 213 sites📍 Grand Rapids📍 St Louis📍 Pittsburgh AstraZeneca · Tests: AZD6750, rilvegostomig A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors NCT06747585Phase 1, Phase 241 sites📍 Scottsdale📍 Fullerton📍 Los Angeles Alentis Therapeutics AG · Tests: ALE.P02, Pembrolizumab Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma NCT07665190Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Becotatug Vedotin and Pucotenlimab A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674Phase 117 sites📍 Duarte📍 Los Angeles📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-1607, Paclitaxel Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial） NCT06509568Phase 21 site📍 Hangzhou Zhejiang Cancer Hospital · Tests: Neoadjuvant chemoradiotherapy followed by immunotherapy, Neoadjuvant chemoimmunotherapy Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma NCT07601737Phase 21 site📍 Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Sc… · Tests: Nimotuzumab Injection, Tislelizumab, Albumin-Bound Paclitaxel /nab-Paclitaxel, Cisplatin (Or Carboplatin), Radical surg… Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma NCT05833594n/a1 site📍 Hefei Anhui Provincial Hospital · Tests: Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs Molecular-Based Selection of Patients with Head and Neck Squamous Cell Carcinoma: Biomarker Analysis NCT06905145n/a1 site📍 Naples National Cancer Institute, Naples · Tests: Biomarkers evaluation Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin NCT07441681Phase 3150 sites📍 Birmingham📍 Anaheim📍 Baldwin Park NRG Oncology · Tests: Biospecimen Collection, Carboplatin, Cetuximab, Computed Tomography, Intensity-Modulated Radiation Therapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy